Mitochondrial dysfunction in cardiomyocytes

Mitochondrial dysfunction in cardiomyocytes refers to a disruption in normal mitochondrial metabolism and signaling within heart muscle cells, leading to inadequate ATP (energy) generation, excessive reactive oxygen species (ROS) production, imbalance in calcium homeostasis, and activation of apoptotic or necrotic pathways[1][3][5]. This state can be caused by genetic mutations in mitochondrial DNA or nuclear-encoded mitochondrial genes, secondary to cardiac stress (ischemia, overload), or systemic diseases. It is a key driver in the pathogenesis of diverse cardiac diseases including heart failure, dilated or hypertrophic cardiomyopathy, and ischemic injury[2][3][7]. Therapeutically, "mitochondrial dysfunction" is a disease process or syndrome rather than a specific molecular target, and efforts to modulate it involve pharmacologically targeting mitochondria as organelles, or their signaling/metabolism, rather than a particular receptor or protein[3][5][6]. **Important note:** "Mitochondrial dysfunction in cardiomyocytes" is not itself a defined, canonical target (such as a receptor, transporter, or enzyme). It is a complex phenotype or pathological process involving multiple molecular targets and mechanisms[1][2][3][5]. For structured drug discovery or target mapping, one would need to specify a particular mitochondrial protein, enzyme, or signaling pathway (e.g., Complex I, PGC1α, or mitofusin-2), rather than this broad cellular mechanism.

Other names

Mitochondrial dysfunction in cardiac muscle cellCardiomyocyte mitochondrial dysfunctionMitochondrial disorder in cardiomyocyte

Enhancement of mitochondrial electron transport chain function Reduction of mitochondrial ROS production/oxidative stress Improvement of mitochondrial biogenesis or mitophagy Restoration of mitochondrial DNA or protein homeostasis Modulation of calcium transport